Australian Cystic Fibrosis Therapeutics Market: Segmented by Disease types (Class 1-5), Drug Class, Geography, Route of Administration and Distribution Channel - Growth, Trends, and Forecasts (2020 2028F)
- Published Date: 2022-12-28
- Report ID: 139976
- Pages: 200
-
Format:
Report Overview
The Australian Cystic Fibrosis Market size stood at around USD xx billion in 2020 and is projected to reach USD xx billion by 2028, exhibiting a CAGR of xx% during the forecast period.
Cystic Fibrosis is a hereditary disorder, which majorly affects lungs and other body parts such as pancreas, liver, and kidney. It is caused by the mutation in the cystic fibrosis transmembrane conductance regulator (CFTR) gene. This gene is located in chromosome number 7, and is responsible for the regulation of sweat, mucus, and body secretions. The average life expectancy forAustralianswithCFis 38. Approximately 3,500 people inAustraliahave CF.
According to the Australian Cystic Fibrosis patient registry report out of the whole population, more than 3446 people are suffering from this disease & 85 % of patients are diagnosed within 1 year after the presence of symptoms are the growth drivers of this market.
Market Drivers
Increased government backing for innovation, as well as increased funding for R&D projects for various Cystic Fibrosis treatments, will propel the market forward. The market's expansion would be hampered by the high cost of Cystic Fibrosis therapy and the emergence of generic medications along with the side effects caused by drugs available.
1. Australian Cystic Fibrosis Market Overview........................
A. Market Size
2. Market Growth Drivers.
A. Growing Burden of Cystic Fibrosis
B. Increased Government Support and funding
C. Launch of Innovative Products
3. Major Cystic Fibrosis Types...........................................................................
A. Protein production mutations (Class 1)
B. Protein processing mutations (Class 2)
C. Gating mutations (Class 3)
D. Conduction mutations (Class 4)
E. Insufficient protein mutations (Class 5)
4. Cystic Fibrosis Market Segmentation........................
A. By Drug Class
I. Pancreatic Enzyme Supplements
II. CFTR Modulators
III. Nutritional Support
IV. Pulmonary therapies
B. By Geography
I. New South Wales
II. Queensland
III. Victoria
IV. Western Australia
V. Southern Australia
VI. Tasmania
VII. Australian Capital Territory
C. By Route of Administration
I. Oral
II. Parenteral
III. Inhalations
D. By Distribution Channel
I. Retail Pharmacies
II. Hospital Pharmacies
III. Online Pharmacies
5. Cystic Fibrosis Major Drugs Market Share
A. Market Analysis, Insights and Forecast By Revenue
6. Competitive Landscape...
A. Major Players
B. Products in Pipeline
7. Key Company Profiles..
A. Vertex Pharmaceuticals Inc. Company overview, Product & Services, Strategies & Financials
B. Gilead Sciences, Inc. Company overview, Product & Services, Strategies & Financials
C. Novartis Company overview, Product & Services, Strategies & Financials
8. Healthcare Policies and Regulatory Landscape
A. Policy changes and Reimbursement scenario
9. Factors Driving Future Growth
A. New Trends and Development of Cystic Fibrosis market
B. Future Opportunities
10. Conclusion
Call Us
( India toll free )
+91 835 605 0278
( US toll free )
+1 800 601 6071
Drop us an email at
sales@prudentmarkets.com
Get your pre and post sales queries resolved by our Subject matter experts.
We will assist you to customize the report to fit your research needs.
Our prime focus is to provide qualitative and accurate data.
Feel free to order a sample report before purchase.
Your personal and confidential information is safe and secured.
